Evidence map›Paper›PMID 31961910›Full record

ArticlePloS one2020

Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage.

Zhi Li, Maxime Rotival, Etienne Patin, Frédérique Michel, Sandra Pellegrini

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal transduction and targeted therapy · 2024
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Strategies to therapeutically modulate cytokine action.Nature reviews. Drug discovery · 2023
    Review
  13. Article
  14. Review
  15. Article
  16. Nature and nurture: understanding phenotypic variation in inborn errors of immunity.Frontiers in cellular and infection microbiology · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Zhi LiUnit of Cytokine Signaling, Institut Pasteur, INSERM U1221, Paris, France.
Maxime RotivalUnit of Human Evolutionary Genetics, Institut Pasteur, CNRS UMR2000, Paris, France.
Etienne PatinUnit of Human Evolutionary Genetics, Institut Pasteur, CNRS UMR2000, Paris, France.ORCID 0000-0002-9911-4459
Frédérique MichelUnit of Cytokine Signaling, Institut Pasteur, INSERM U1221, Paris, France.
Sandra PellegriniUnit of Cytokine Signaling, Institut Pasteur, INSERM U1221, Paris, France.ORCID 0000-0001-5837-7589
Inserm · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TYK2 belongs to the JAK protein tyrosine kinase family and mediates signaling of numerous antiviral and immunoregulatory cytokines (type I and type III IFNs, IL-10, IL-12, IL-22, IL-23) in immune and non-immune cells. After many years of genetic association studies, TYK2 is recognized as a susceptibility gene for some inflammatory and autoimmune diseases (AID). Seven TYK2 variants have been associated with AIDs in Europeans, and establishing their causality remains challenging. Previous work showed that a protective variant (P1104A) is hypomorphic and also a risk allele for mycobacterial infection. Here, we have studied two AID-associated common TYK2 variants: rs12720270 located in intron 7 and rs2304256, a non-synonymous variant in exon 8 that causes a valine to phenylalanine substitution (c.1084 G > T, Val362Phe). We found that this amino acid substitution does not alter TYK2 expression, catalytic activity or ability to relay signaling in EBV-B cell lines or in reconstituted TYK2-null cells. Based on in silico predictions that these variants may impact splicing of exon 8, we: i) analyzed TYK2 transcripts in genotyped EBV-B cells and in CRISPR/Cas9-edited cells, ii) measured splicing using minigene assays, and iii) performed eQTL (expression quantitative trait locus) analysis of TYK2 transcripts in primary monocytes and whole blood cells. Our results reveal that the two variants promote the inclusion of exon 8, which, we demonstrate, is essential for TYK2 binding to cognate receptors. In addition and in line with GTEx (Genetic Tissue Expression) data, our eQTL results show that rs2304256 mildly enhances TYK2 expression in whole blood. In all, these findings suggest that these TYK2 variants are not neutral but instead have a potential impact in AID.

Indexed as

Genetic Predisposition to DiseaseAllelesAmino Acid SubstitutionAutoimmune DiseasesB-LymphocytesCytokinesGene Expression RegulationGenetic Association StudiesGenotypeHumansInflammationPhenylalaninePolymorphism, Single NucleotideQuantitative Trait LociTYK2 KinaseCytokinesPhenylalanineTYK2 KinaseTYK2 protein, human

Identifiers

PMID31961910
PMCPMC6974145
OpenAlexW3000899691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.